5,564 Shares in Hologic, Inc. (NASDAQ:HOLX) Bought by Centaurus Financial Inc.

Centaurus Financial Inc. purchased a new stake in Hologic, Inc. (NASDAQ:HOLX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 5,564 shares of the medical equipment provider’s stock, valued at approximately $453,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Janus Henderson Group PLC increased its position in Hologic by 29.5% during the 1st quarter. Janus Henderson Group PLC now owns 99,707 shares of the medical equipment provider’s stock valued at $7,773,000 after purchasing an additional 22,732 shares during the period. B. Riley Wealth Advisors Inc. increased its position in shares of Hologic by 13.0% during the first quarter. B. Riley Wealth Advisors Inc. now owns 3,198 shares of the medical equipment provider’s stock worth $249,000 after buying an additional 367 shares during the period. California State Teachers Retirement System raised its stake in Hologic by 0.5% during the first quarter. California State Teachers Retirement System now owns 411,051 shares of the medical equipment provider’s stock worth $32,046,000 after buying an additional 1,988 shares during the last quarter. Tidal Investments LLC lifted its holdings in Hologic by 10.8% in the first quarter. Tidal Investments LLC now owns 16,901 shares of the medical equipment provider’s stock valued at $1,317,000 after buying an additional 1,654 shares during the period. Finally, Comerica Bank boosted its position in Hologic by 40.9% during the first quarter. Comerica Bank now owns 110,053 shares of the medical equipment provider’s stock valued at $8,580,000 after acquiring an additional 31,967 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

HOLX has been the topic of a number of recent analyst reports. Evercore ISI boosted their price objective on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. Royal Bank of Canada boosted their price target on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 5th. Raymond James lifted their price objective on shares of Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Finally, Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $89.91.

Hologic Stock Down 0.9 %

HOLX stock opened at $79.00 on Wednesday. The firm has a market capitalization of $18.35 billion, a PE ratio of 23.72, a P/E/G ratio of 2.49 and a beta of 0.98. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a twelve month low of $67.59 and a twelve month high of $84.67. The stock’s 50 day moving average is $80.38 and its 200-day moving average is $78.38.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. The business had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business’s revenue was up 4.5% on a year-over-year basis. During the same period last year, the business earned $0.89 EPS. Sell-side analysts expect that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.